NASDAQ:ROSG - Rosetta Genomics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.4299 0.00 (0.00 %) (As of 09/21/2018 04:00 PM ET)Previous Close$0.4299Today's Range$0.4201 - $0.439052-Week Range$0.23 - $2.75Volume169,599 shsAverage Volume81,512 shsMarket Capitalization$2.55 millionP/E RatioN/ADividend YieldN/ABeta0.49 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel. Receive ROSG News and Ratings via Email Sign-up to receive the latest news and ratings for ROSG and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:ROSG CUSIPN/A Webwww.rosettagenomics.com Phone972-73-222-0700 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$9.23 million Price / Sales0.28 Cash FlowN/A Price / CashN/A Book Value$2.41 per share Price / Book0.18 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees86 Outstanding Shares5,930,000Market Cap$2.55 million Rosetta Genomics (NASDAQ:ROSG) Frequently Asked Questions What is Rosetta Genomics' stock symbol? Rosetta Genomics trades on the NASDAQ under the ticker symbol "ROSG." How were Rosetta Genomics' earnings last quarter? Rosetta Genomics (NASDAQ:ROSG) posted its quarterly earnings data on Thursday, May, 19th. The medical research company reported ($0.18) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.16) by $0.02. The medical research company earned $2.60 million during the quarter, compared to the consensus estimate of $3.36 million. View Rosetta Genomics' Earnings History. What price target have analysts set for ROSG? 1 equities research analysts have issued 1-year price objectives for Rosetta Genomics' stock. Their predictions range from $0.02 to $0.02. On average, they anticipate Rosetta Genomics' share price to reach $0.02 in the next year. This suggests that the stock has a possible downside of 95.3%. View Analyst Price Targets for Rosetta Genomics. What is the consensus analysts' recommendation for Rosetta Genomics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rosetta Genomics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Rosetta Genomics. Who are some of Rosetta Genomics' key competitors? Some companies that are related to Rosetta Genomics include Sonoma Pharmaceuticals (SNOA), Parnell Pharmaceuticals (PARNF), Peak Pharmaceuticals (PKPH), Cellectar Biosciences (CLRB), Concordia International (CXRX), International Stem Cell (ISCO), Reliv International (RELV), ContraVir Pharmaceuticals (CTRV), Ritter Pharmaceuticals (RTTR), Immune Therapeutics (IMUN), MYOS (MYOS), Flex Pharma (FLKS), Stellar Biotechnologies (SBOT), Sunwin Stevia International (SUWN) and iCo Therapeutics (ICOTF). Who are Rosetta Genomics' key executives? Rosetta Genomics' management team includes the folowing people: Mr. Kenneth A. Berlin, Pres & CEO (Age 54)Mr. Ron Kalfus CPA, Chief Financial Officer (Age 44)Mr. Oded Biran Adv., Gen. Counsel and Sec. (Age 39)Dr. Eti Meiri Ph.D., VP of Research (Age 50)Ms. Ana C. Ward Esq., M.S.,M.B.A., Exec. VP of Legal and Corp. Devel. Has Rosetta Genomics been receiving favorable news coverage? News coverage about ROSG stock has been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Rosetta Genomics earned a news impact score of 0.18 on Accern's scale. They also gave news articles about the medical research company an impact score of 46.57 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Rosetta Genomics. How do I buy shares of Rosetta Genomics? Shares of ROSG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Rosetta Genomics' stock price today? One share of ROSG stock can currently be purchased for approximately $0.4299. How big of a company is Rosetta Genomics? Rosetta Genomics has a market capitalization of $2.55 million and generates $9.23 million in revenue each year. Rosetta Genomics employs 86 workers across the globe. How can I contact Rosetta Genomics? Rosetta Genomics' mailing address is 10 PLAUT STREET SCIENCE PARK, REHOVOT L3, 76706. The medical research company can be reached via phone at 972-73-222-0700 or via email at [email protected] MarketBeat Community Rating for Rosetta Genomics (NASDAQ ROSG)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 146 (Vote Outperform)Underperform Votes: 117 (Vote Underperform)Total Votes: 263MarketBeat's community ratings are surveys of what our community members think about Rosetta Genomics and other stocks. Vote "Outperform" if you believe ROSG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ROSG will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/22/2018 by MarketBeat.com StaffFeatured Article: What Is An Exchange-Traded Fund (ETF)?